EXACT Sciences Corporation (NASDAQ: EXAS) announced today it has received notice from the NASDAQ Listing Qualifications Panel (the “Panel”) that the Company’s common stock will be transferred from The NASDAQ Global Market to The NASDAQ Capital Market. The transfer will be effective with the open of trading on Friday, November 28, 2008. The Company’s shares will continue to trade under the ticker “EXAS” while on The NASDAQ Capital Market. Despite this transfer, the Panel may still determine to delist the Company at any point in time pending further analysis of the Company’s plans for demonstrating compliance with the listing requirements for the NASDAQ Capital Market.

In that regard, EXACT does not currently meet the continued listing requirements of The NASDAQ Capital Market. The Panel determined to list the Company's securities on The NASDAQ Capital Market on a conditional basis, pending its review of additional information it has requested from EXACT regarding the Company’s plan to regain compliance with the continued listing requirements. There can be no assurance that the Panel will continue the conditional listing of the Company's securities on The NASDAQ Capital Market following its review of the supplemental information, which may be completed in early December 2008.

The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ’s corporate governance standards.

About EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop patient-friendly screening technologies for use in the detection of cancer. The Company has 115 patents in the United States and abroad, with key intellectual property assets applicable to the field of reproductive health and oncology. EXACT maintains an exclusive license agreement in the United States and Canada with Laboratory Corporation of America® Holdings (LabCorp®) allowing LabCorp to offer a testing service based on certain of EXACT Sciences’ intellectual property. EXACT continues to retain rights to offer a testing service itself within the United States, to develop a U.S. Food and Drug Administration cleared or approved in vitro diagnostic test kit, and rights to license its technologies outside of the United States and Canada. EXACT Sciences’ stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer (a group comprised of representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy), and the American College of Radiology. EXACT Sciences is based in Marlborough, Mass.

Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements. These forward-looking statements relate to, among other things, EXACT Sciences' expectations concerning the transfer of its common stock listing from the NASDAQ Global Market to the NASDAQ Capital Market and its ability to remain listed on the NASDAQ Capital Market. These forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.